Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 8/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 8/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4387141 | 0.79 | LMNA (0.33) | MAPTLMNA | |
| SCHEMBL2858252 | 0.79 | BACE1 (0.35) | ALDH1A1KDM4EMAPTCYP2D6LMNA | |
| SCHEMBL2863612 | 0.77 | TNFRSF1A (0.32) | — | |
| SCHEMBL4380682 | 0.73 | SIGMAR1 (0.40) | ALDH1A1SIGMAR1KDM4ECYP2D6TSHR | |
| SCHEMBL4381965 | 0.72 | F2 (0.31) | KDM4E | |
| SCHEMBL4384082 | 0.72 | L3MBTL1 (0.34) | ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL2866362 | 0.72 | DHODH (0.32) | ALDH1A1MAPTCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL3624731 | 0.70 | TLR9 (0.32) | — | |
| SCHEMBL4382475 | 0.66 | EGFR (0.37) | LTB4RLTB4R2ALDH1A1SIGMAR1MAPT | |
| SCHEMBL2864972 | 0.66 | ALDH1A1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | LTB4R 3831/4885LTB4R2 4504/4885ALDH1A1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.